African Journal of

  • Abbreviation: Afr. J. Biotechnol.
  • Language: English
  • ISSN: 1684-5315
  • DOI: 10.5897/AJB
  • Start Year: 2002
  • Published Articles: 12294

Full Length Research Paper

Autologous bone marrow mononuclear cell delivery to dilated cardiomyopathy patients: A clinical trial

  P. L. N Kaparthi1*, Gupta Namita2, Lakshmi K. Chelluri2, V. Surya Prakasa Rao1, P. Kantilal Shah1, Adavi Vasantha2, S. Kamaraju Ratnakar2 and K.Ravindhranath1        
  1Department of Cardiology, Global Hospitals, Lakdi-ka-Pool, Hyderabad –500 004 (A.P), India. 2Department of Transplant Biology and Stem Cell, Global Hospitals, Lakdi-ka-Pool, Hyderabad –500 004 (A.P), India.
Email: [email protected]

  •  Accepted: 10 December 2007
  •  Published: 05 February 2008



The impact of intracoronary autologous bone marrow mononuclear cells (BMMC) in patients with DCM (dilated cardiomyopathy) with severe left ventricular (LV) dysfunction was assessed. The study included five DCM patients (age group 20 - 65 years) with ejection fraction (EF) of ≤ 30%. Mononuclear cells (Mean MNC count: 9.16 x 107 and Mean CD34 positive cell count: 3.68 x 105) were infused through intracoronary injection into the patients. Left ventricular ejection fraction (LVEF) was increased from 25 - 30% to 40 - 45% (approximately 500,000 CD34 + cells) in two of the patients. Conclusively, bone marrow mononuclear cell therapy has a potential to be considered a standard therapeutic entity for the treatment of dilated cardiomyopathy with severe LV dysfunction.


Key words: Mononuclear cells, dilated cardiomyopathy, autologous, intra-coronary